Source: Kapitales Research

Highlights:

• Counter-drone specialist secures AU$24.9 million US defence contract.
• Lung imaging innovator launches trial targeting larger US market.
• Execution milestones could determine the next phase of growth.

Momentum Builds Across ASX StocksStocks continued yesterday’s momentum as investors responded positively to fresh growth announcements from the healthcare and defence technology sectors. Both companies unveiled developments aimed at expanding their addressable markets and strengthening long-term revenue opportunities, drawing strong market interest.Stocks in Focus: 

• DroneShield Limited (ASX: DRO) traded at AU$3.210 with the stocks rising approximately 3.50%.
• 4DMedical Limited (ASX: 4DX) changed hands at AU$4.330, with the stocks surging approximately 5.90%.

Counter-Drone Defence MomentumDroneShield’s latest gains followed the announcement of a AU$24.9 million contract supporting the US Department of War’s Joint Interagency Task Force 401 (JIATF-401), a key organisation focused on counter-unmanned aerial systems capabilities. The agreement includes an initial committed value of AU$19.3 million, alongside an additional AU$5.6 million in optional scope over a five-year period. The contract covers the delivery of mobile and fixed-site counter-drone systems, including hardware, software subscriptions, warranties, and support services. Deliveries are scheduled across 2026 and 2027, with at least AU$10 million expected to be recognised as committed revenue in FY26 and the balance in FY27.The announcement reinforces DroneShield’s growing presence in the US defence market, where demand for counter-drone technologies continues to rise amid evolving aerial security threats. Management noted that customers increasingly require rapidly deployable and scalable solutions capable of protecting critical infrastructure, personnel, and operational assets. The contract also highlights confidence in DroneShield’s ability to deliver integrated defence systems at scale, further strengthening its position within a rapidly expanding global market.Medical Imaging Expansion4DMedical advanced after launching its CLEAR (Contrast-free Lung Evaluation for Acute Risk in Pulmonary Embolism) clinical evidence program, a strategic initiative designed to accelerate adoption of its CT:VQ™ technology in the acute pulmonary embolism market.The company believes the program could significantly expand its US market opportunity. While CT:VQ™ is already positioned to compete within the nuclear ventilation-perfusion imaging segment, CLEAR aims to support entry into the much larger CT pulmonary angiography market. Management estimates this could increase the obtainable US market to approximately US$3 billion, supported by around five million annual imaging studies.A central component of the program is a prospective, multinational clinical study comparing CT:VQ™ directly with current standard-of-care imaging techniques in patients suspected of pulmonary embolism. To support the initiative, 4DMedical has entered a clinical research agreement with Mass General Brigham, with Massachusetts General Hospital serving as the lead study site. The company has committed approximately US$2 million to fund patient recruitment, imaging analysis, and clinical data generation.Outlook and Future ProspectsThe market’s reaction suggests investors are rewarding companies capable of creating clear pathways to future growth. For DroneShield, the latest contract adds revenue visibility and strengthens its foothold in a strategically important defence market. Meanwhile, 4DMedical’s clinical program has the potential to unlock a substantially larger healthcare opportunity if adoption targets are achieved. Looking ahead, investors will be closely watching contract execution milestones at DroneShield and clinical study progress at 4DMedical. Successful delivery against these objectives could provide further catalysts as both companies seek to convert emerging opportunities into sustained commercial growth.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au